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Abstract
Extracellular signal-regulated kinase 8 (ERK8) has been already implicated in cell transformation and in the protection of
genomic integrity and, therefore, proposed as a novel potential therapeutic target for cancer. In the absence of a crystal
structure, we developed a three-dimensional model for its kinase domain. To validate our model we applied a structure-
based virtual screening protocol consisting of pharmacophore screening and molecular docking. Experimental
characterization of the hit compounds confirmed that a high percentage of the identified scaffolds was able to inhibit
ERK8. We also confirmed an ATP competitive mechanism of action for the two best-performing molecules. Ultimately, we
identified an ERK8 drug-resistant ‘‘gatekeeper’’ mutant that corroborated the predicted molecular binding mode,
confirming the reliability of the generated structure. We expect that our model will be a valuable tool for the development
of specific ERK8 kinase inhibitors.
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Introduction
The ease and the rate of genome sequencing are higher today
than ever before. Conversely, experimental techniques for protein
structure determination are characterized by a much slower rate,
entailing that three-dimensional (3D) structure for many potential
drug targets will likely be not experimentally solved but predicted
instead. For this reason, modeled structures obtained by compu-
tational techniques, once validated, will represent an irreplaceable
reservoir for modern drug design and development. In this
context, in the last 10–15 years, protein kinases have become
particularly interesting drug targets for pharmaceutical industry.
In cancer research only, over 50% of the current projects are
indeed estimated to focus on kinase targets [1].
There are around 500 members of the protein kinase
superfamily encoded by the human genome, whose degree of
similarity in the catalytic domain poses many challenges to develop
really specific inhibitors targeting the ATP cavity [2]. Still, this
similarity is the property that can be also exploited for structural
modeling. In turn, such 3D knowledge will be important to predict
sensitivity to ATP competitive inhibitors and represents the
rationale for the development of more specific compounds (not
only type I inhibitors, but also type II inhibitors and type III or
allosteric inhibitors) [3]. Importantly, the predictive value of a
reliable 3D structure will be also a useful tool to rationally
modulate a possible second-line therapy when resistance arises.
Mitogen-activated protein kinases (MAPKs) regulate evolution-
arily conserved signaling pathways affecting all essential cellular
functions. For this reason, abnormalities in MAPKs signaling also
play a critical role in the development and progression of cancer
[4]. Extracellular signal-regulated kinase 8 (ERK8, MAPK15) is
the last identified member of the MAPK family [5]. It is a proline-
directed serine/threonine kinase featuring the distinctive Thr-
Xaa-Tyr (TXY) motif in the activation loop [6], whose post-
translational modifications appears to be performed through
autophosphorylation [7]. Still, its activity can be further modulat-
ed by serum, DNA-damage and human oncogenes [5,8,9].
Importantly, ERK8 has been implicated in cell transformation
[10], in the protection of genomic integrity [11], and has been
described as a potent regulator of telomerase activity [12] and of
the autophagic process [13]. Consequently, it has been proposed
as a novel therapeutic target for cancer. Ultimately, ERK8 has
been also reported to stimulate the activity of the JUN proto-
oncogene [10] and to reduce the activity of different nuclear
receptors [14,15]. Specific ERK8 inhibitors would thus represent
useful tools for the study of its still poorly characterized signaling
pathways and could confirm the clinical potential of ERK8
targeting for cancer therapy.
With the aim of developing a 3D structure of ERK8, we took
advantage of the similarity of its ATP-binding domain to other
MAPKs for structural modeling. Once obtained, we successfully
confirmed the reliability of our model by applying a structure-
based virtual screening protocol that allowed us to identify
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molecular scaffolds able to inhibit ERK8 kinase activity. Impor-
tantly, we confirmed the binding of such molecules to the ERK8
ATP binding pocket both by ATP competition assays and by using
the first reported ERK8 drug-resistant ‘‘gatekeeper’’ mutant.
Overall, our experimental data clearly sustain the predictive ability
of the generated model for the ERK8 kinase domain and promise
its utility in a drug-design perspective.
Materials and Methods
Homology Modeling
All the primary sequences were obtained from UniPROT
protein sequence database [16]. Sequence similarity searches were
carried out using BlastP [17]. Based on previous homology
modeling studies on protein kinases [18], sequence alignment was
performed by CLUSTAL W [19] with a gap open penalty of 10
and a gap extension penalty of 0.05. Also other parameters were
kept at their default values. The alignment was also tested with the
standard protocol of the T-Coffee method [20] (Fig. S1). The
crystal structure of FUS3, ERK2, p38a and CDK2 were from the
Protein Data Bank [21]; entries ID: 2B9F [22], 1ERK [23], 1P38
[24], 1HCK [25].
The kinase domain of ERK8 (residues 12-345) was obtained
using Modeller 9v5 package [26]. The best protein model was
chosen on the basis of the DOPE (Discrete Optimized Protein
Energy) assessment method as implemented in Modeller. Cartoons
were prepared with Pymol software (The PyMOL Molecular
Graphics System, Version 1.2r3pre, Schro¨dinger, LLC).
Molecular Dynamics simulations
The AMBER10 program [27] was used for relaxing protein
coordinates by means of energy minimization and molecular
dynamics simulations. The ff99 and the GAFF force fields were
used for protein and organic ligands, respectively. A rectilinear
box of TIP3P water molecules buffering 12 A˚ was added to solvate
the Mg++ ERK8/ADP complex, while Cl2 counterions were
added to neutralize the system. Energy minimization was
performed by using a combination of the steepest descent and
the conjugate gradient algorithms. First, the solvent was energy
minimized while keeping solute’s coordinates frozen. Then, the
solute alone was energy minimized prior to relax the whole
solvated complex. The system was then heated to 300 K for
100 ps and the density was equilibrated for 100 ps before
producing MD trajectories. The SHAKE algorithm was used to
restrain bonds involving H atoms. A time-step of 1 fs was used.
The unbound approach for Mg++ ions was applied. Mg++ and
ADP were restrained by a force constant decreasing from 25 to
0 kcal/mol?A˚2 during the first 1 ns of MD simulation. Unre-
strained trajectories were produced for 1.5 ns (Fig. S3).
Pharmacophores
Ligand-based pharmacophore models were generated by using
the ‘‘Common Feature Pharmacophore Generation’’ protocol of
Discovery Studio 2.5 (Discovery Studio, v2.5. San Diego: Accelrys
Software Inc., 2009) on a training set of molecules known to
inhibit ERK8 [28]. With this method, two different pharmaco-
phore models were generated, composed of 4 and 5 features,
respectively.
Structure-based pharmacophore models were generated by
following two different approaches: 1) the Ligandscout 3.0
software [29] was used to derive a pharmacophore model
accounting for the interactions performed by ADP toward Mg++
loaded ERK8, starting from the representative structure obtained
by MD simulations (the refined ERK8 structure). Features
accounting for the interaction of phosphate groups with the Mg
ion were manually removed; 2) the GRID software (GRID 22;
Molecular Discovery Ltd.) [30] was used to explore possible
molecular determinants involved in ligand binding within the
ERK8 active site, as generated by MD simulation. Starting from
the representative MD structure, coordinates of ADP and Mg++
were removed. Selected probe atoms were: O (sp2 carbonyl
oxygen), DRY (the hydrophobic core), C3 (methyl CH3 group),
C1 = (sp2 CH aromatic or vinyl), N1 (neutral flat NH, e.g. amide),
O1 (alkyl hydroxyl OH group), N: (sp3 N with lone pair). Points of
energy minimum were converted into pharmacophoric features
according to the GBPM approach [31].
Molecular Docking
Docking calculations were performed by using the GOLD
program, version 4.1.2 [32]. The Chemscore scoring function
[33,34] was used, as it is able to finely reproduce the binding mode
of ADP described in the refined ERK8 structure. Default
parameters of the Genetic Algorithm (GA) were used, whereas
the efficiency was set at 150%. Twenty runs for each ligand were
generated by the GA, allowing the early termination after 5
consecutive runs having a root mean square deviation (rmsd)
below the tolerance limit of 1.5 A˚. The binding site was centered
on the side chain of leucine 144 and had a radius of 16 A˚.
Expression Vectors
Bacterial expression vector pGEX4T3-ERK8 was generated by
subcloning the ERK8 cDNA, obtained by restriction enzyme
digestion from the already described pCEFL-HA-ERK8 [8], into
the pGEX4T3 vector in frame with the GST tag. ERK8
gatekeeper mutants were generated using the QuikChange site-
directed mutagenesis kit (Stratagene), using pGEX4T3-ERK8 as a
template. pGEX4T3-ERK8 kinase dead (KD) was generated
subcloning ERK8 K42R cDNA (kindly provided by M. Abe) into
the pGEX4T3 vector. The identity and integrity of all the vectors
were confirmed by DNA sequencing.
Bacterial expression of GST-fusion proteins
The BL21 Lys strain of Escherichia coli (E. coli) was transformed
with the pGEX4T3 vectors encoding for the full-length form of
ERK8 protein and of the different mutants. Bacterially expressed
GST-fusion proteins were purified as previously described [35].
The baculovirus-expressed GST-fusion ERK8 protein is from
Carna Biosciences, Inc.
Reagents
Ro-318220 is from Calbiochem; radiolabeled [c-32P] ATP is
from PerkinElmer; screened compounds are from Asinex.
In vitro Kinase Assay
Purified GST-fusion protein (50 ng/sample) was incubated
30 min at 30uC in kinase buffer [25 mM HEPES (pH 7.6),
0.1 mM Na3VO4, 20 mM b-glycerophosphate, 2 mM DTT,
20 mM MgCl2] with 5 mg/sample of MBP (Sigma) as generic
substrate, 2.5 mCi [c-32P]ATP and unlabeled ATP (final concen-
tration 5 mM) [28], unless differently indicated. Candidate
compounds dissolved in dimethyl sulfoxide (DMSO) were added
as needed (an equal volume of DMSO was added to control
samples). Reaction was stopped adding 5X Laemmli buffer and
resolved by SDS-PAGE. Dried gels were then exposed to
phosphorimager (Typhoon 8600, Molecular Dynamics) and 32P
incorporation on MBP was estimated by densitometry (Image-
Quant TL Software, GE Healthcare).
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Alternatively, for samples to be analyzed by liquid scintillation
counter, reaction mixture was spotted (after incubation at 30uC for
30 minutes in the same kinase buffer described above) on
Whatman (P81) 3MM paper and immediately immersed in 1%
phosphoric acid to terminate the reaction [36]. After four washes
with fresh phosphoric acid, scintillant solution was added
(BioFluor, PerkinElmer) and 32P incorporation of triplicates was
measured with a b-counter scintillator (TRI-CARB 2000,
Packard). All the assays were replicated twice and the means of
the replicates were calculated. For Coomassie staining, before
adding radiolabeled ATP, an aliquot of each sample prepared for
kinase assay was loaded on SDS-PAGE gel, stained with
SimplyBlue SafeStain (Invitrogen), and revealed using the Odyssey
Infrared Imaging System (Li-Cor Biosciences).
Western Blots
Proteins in storage buffer (50 mM Tris pH 8.0, 0.5 mM DTT,
0,5 mM EDTA and 10% glycerol) were loaded on SDS-PAGE
gel, transferred to Immobilon-P PVDF membrane (Millipore),
probed with anti-ERK8 primary antibody (custom preparation)
and secondary antibody HRP-conjugated anti-rabbit IgGs (Santa
Cruz Biotechnology), and revealed by enhanced chemo-lumines-
cence detection (ECL Plus; GE Healthcare).
Results
Homology Modeling
ERK8 is a 544-amino acid protein with a typical MAPK
catalytic domain and a peculiarly long C-terminal extension [5].
The degree of conservation of the catalytic domain, as compared
with other MAPKs, is adequate to predict its 3D structure by
means of homology modeling procedure, whereas the C-terminal
region does not share a significant sequence identity with any
known protein, thus impeding any attempt of modeling the whole
protein structure with this approach. Therefore, we generated a
3D structure of the ERK8 kinase domain by homology modeling
procedure, in the perspective of obtaining a reliable model to next
screen for novel ERK8-directed ATP competitive scaffolds. We
selected FUS3 (S. cerevisiae MAPK) and ERK2 X-ray structures as
templates, featuring a percentage of sequence identity with ERK8
kinase domain of 45% and 44%, respectively (similarity is 64%
and 62%, respectively) (Fig. 1A). This degree of homology
guaranteed a high-quality model structure [37]. In this context,
while we used ClustalW as our leading program to align all the
sequences, in order to get a higher confidence on the ability to
correctly align motifs and domains, we also tested the multiple
sequence alignment with T-Coffee (Fig. S1), another widely used
method. As expected, we obtained almost complete identity of the
two final alignments in the core catalytic unit.
While featuring high homology with most of FUS3 and ERK2
kinase domains, the last thirty residues of ERK8 kinase domain
did not share such high homology with the selected proteins and
also provided lower level of agreement between the two methods
of alignment (Fig. 1A and Fig. S1). Therefore, we decided to
include a third template, namely p38a, which shares higher
homology with ERK8 in this particular segment obtaining the
final alignment reported in Figure 1A. Based on this alignment, we
next performed homology modeling using Modeller 9v5 [26]. Out
of the twenty models that we generated, the top five showed a
backbone rmsd lower than 1.5 A˚. Accordingly, the model having
Mg++ and ADP within the catalytic active site, endowed with the
lower DOPE score was selected as our ERK8 model. The
structure showed the overall MAPK topology with an N-terminal
and a C-terminal lobe forming the catalytic groove (Fig. 1B).
Superimposition of the modeled ERK8 structure with correspond-
ing atoms of ERK2 (Fig. 1C) and FUS3 (Fig. S2) templates
resulted in a rmsd for Ca atoms of ,1 and 1.2 A˚, respectively.
This model was further refined by means of standard in silico
procedures to optimize protein-ligand complex structure for ligand
design approaches [38].
Molecular Dynamics Simulation
The structure of ERK8 generated by homology modeling was
relaxed by means of a Molecular Dynamics (MD) simulation. With
respect to our previous approach to protein kinases study [18],
where the homology model was relaxed by means of energy
minimization, here we further used MD simulations to better
account for protein flexibility [39]. In detail, the system was first
solvated and neutralized by the addition of counterions to
resemble a physiological situation. Next, energy minimization
was performed to solve bad contacts prior to heating and
equilibrating the system, and eventually generating unrestrained
MD trajectories for 1.5 ns. As expected for kinase proteins in
complex with a ligand, the system was highly stable during the
time of simulation [18,39,40], especially within the ATP binding
site (Fig. S3). Therefore, we considered 1.5 ns a sufficient amount
of time to refine this protein structure before performing a
structure-based virtual screening. The average structure was
calculated, whereas the frame with the lowest rmsd with respect
to the average structure was considered representative for the
system, and used for structural considerations, as well as for further
studies (Fig. 1D). Psi and Phi angles of protein residues, taken from
the representative structure, were plotted over a Ramachandran
map showing that 99% residues were in the most favorable or
additional allowed regions, whereas only three residues (1%) were
in disallowed regions. However, these latter residues were
significantly far from the ATP binding site. The representative
structure resulting from MD simulations (hereafter referred to as
refined ERK8), that showed a ,2 A˚ rmsd for Ca atoms in
comparison to corresponding atoms in ERK2 (Fig. 1E), was first
validated by self-docking ADP within the catalytic site by using the
GOLD docking program (see below). The docking-based binding
pose of ADP was very similar (rmsd ,1.5 A˚) to that found in the
refined ERK8, and to the crystallographic ligand pose within the
active site of the template FUS3 (Fig. S2) [22].
Structure-based pharmacophores and molecular docking
Pharmacophore models represent a useful tool to filter large
compound libraries on the basis of steric and electronic
requirements. In this virtual screening campaign, the generation
of structure-based pharmacophores was allowed by the availability
of the refined ERK8 structure generated by homology modeling
and MD, as reported above (Fig. 2). Pharmacophores were built
by using two different strategies: one – the Ligandscout software
[29] was used to transform the ADP interaction pattern within the
catalytic site of the refined ERK8 strucure into a pharmacophore
model, which was composed of three hydrophobic, one H-bond
acceptor, one H-bond donor and 19 exclude volume features
(Fig. 3A, left panel). Two – the GRID-based pharmacophore
modeling approach (GBPM) [30,31] was applied to generate a
pharmacophore model which accounted for the space regions
endowed with the lowest interaction energy for representative
probe atoms within the catalytic site of ERK8 (Fig. 3A, right
panel). This model was composed of two hydrophobic, one H-
bond donor, two H-bond acceptor and one excluded volume
features. After format conversion, necessary to allow compatibility
with Discovery Studio (Accelrys), pharmacophore models were
used as 3D queries to filter the Asinex library of compounds (about
A 3D Model of the ERK8 MAPK
PLOS ONE | www.plosone.org 3 January 2013 | Volume 8 | Issue 1 | e52011
A 3D Model of the ERK8 MAPK
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e52011
400,000 small molecules) using a procedure previously described
[41]. The 15,527 compounds that survived to the structure-based
pharmacophore filtration were submitted to the following docking
step.
Indeed, we reckoned that the ability to identify ATP compet-
itive compounds by molecular docking, relying on the kinase
domain model of ERK8, might represent a good approach to
corroborate the structure itself. Accordingly, the refined ERK8
structure was used as a rigid receptor in a docking-based hit
identification procedure. The GOLD program (version 4.1.2) [32]
was used with the Chemscore scoring function [33,34]. Docked
compounds were sorted on the basis of their score and the three
top-ranking poses of the first 250 molecules were visually inspected
within the catalytic active site of ERK8. Molecules showing a clear
overlapping between the three poses (rmsd ,1.0 A˚) were deemed
top priority. Based on the predicted binding mode as well as on
chemical diversity criteria, the most promising 25 virtual hits were
selected for further experimental investigation (Fig. 2).
Ligand-based pharmacophores
Beside the structure-based virtual screening approach, a ligand-
based strategy for hit identification was also attempted, based on
the activity data of 18 pan-kinase inhibitors (Fig. S4) toward ERK8
[28]. In general, although results of structure- and ligand-based
approaches are not superimposable, combination of different
strategies could enhance the probability to identify chemically
diverse molecular scaffolds, especially when performing the first
round of a computer-aided drug design approach toward a given
target system.
Two ligand-based common feature pharmacophore models
were generated by using Discovery Studio 2.5, starting from
known ERK8 inhibitors [28]. The first model was composed of
two hydrophobic, one H-bond acceptor and one H-bond donor
features, whereas the second model was composed of two
hydrophobic, one aromatic ring, one H-bond donor and one H-
bond acceptor features (Fig. 3B). Notably, these pharmacophores
are significantly different from each other and from structure-
based models. Ligand-based pharmacophores were used as 3D
queries to filter the Asinex database, the resulting compounds were
inspected for chemical diversity, and the selected 32 putative hits
were submitted to experimental investigation (Fig. 2).
Experimental Screening
To assess the effect of in silico-selected compounds on ERK8
catalytic activity, we generated an N-terminal, GST-tagged form
of the full-length protein in E. coli. In a classical kinase assay with
radiolabeled ATP, bacterially expressed GST-ERK8 was found to
be constitutively active (data not shown), as previously described
[7]. We, therefore, monitored ERK8 ability to phosphorylate a
typical substrate, Myelin Basic Protein (MBP) [28] in the presence
of each candidate compound at a fixed concentration of 50 mM.
As a positive control of ERK8 catalytic inhibition, we used the
ATP competitive inhibitor Ro-318220. This molecule, originally
developed as a protein kinase C (PKC) inhibitor [42], has been
already proven to potently inhibit ERK8 [7,12,13]. By this
approach, we tested the 32 compounds obtained from the ligand-
based virtual screening and the 25 coming from the structure-
based virtual screening. In order to classify the analyzed
compounds in a binary fashion, we set a threshold at 50% of
Figure 1. ERK8 kinase domain model. (A), Multiple sequence alignment between ERK8 and the selected templates FUS3 and ERK2. Numbering is
referred to human ERK8 cDNA sequence as defined in Uniprot accession number Q8TD08. Consensus code: ‘‘yellow’’ indicates positions which have a
single, fully conserved residue; ‘‘green’’ indicates conservation between groups of strongly similar properties; ‘‘blue’’ indicates conservation between
groups of weakly similar properties. Gatekeeper residue is in bold and indicated by a full black circle. The TEY activation motif is in red (activation loop
spans from the DFG motif to the APE motif, residues 155–187). The region in square brackets has been substituted (starting from the position
indicated with the dashed red line) with the alignment highlighted in the bottom square that includes p38a. (B), Model of the ERK8 kinase domain
(residues 12–345 of the full-length 1–544 protein) obtained by means of homology modeling protocol. Conserved kinase domain features are
indicated, b-sheets colored in yellow, a-helices colored in red, loops colored in green, TEY activation motif colored in blue. (C), Superimposition of the
same ERK8 model (grey) with the ERK2 template (purple). (D), Evolution of ERK8 structure with the MD refinement. Superimposition of the ERK8
model (grey), used as MD input, with the representative final structure (the refined ERK8 structure) (cyan) obtained after the simulation. (E),
Superimposition of the refined ERK8 model (cyan) with the ERK2 template (purple).
doi:10.1371/journal.pone.0052011.g001
Figure 2. Flowchart of the in silico protocol. Computational steps
applied to select all the hit compounds to be tested in vitro. In each set
the percentage of success rate refers to the ratio between the number
of active molecules and the number of tested molecules in the
following experimental screening: purified GST-ERK8 protein (50 ng/
sample) was used in kinase assays. Candidate compounds were
dissolved in dimethyl sulfoxide (DMSO) and tested at fixed concentra-
tion of 50 mM (an equal volume of DMSO was added to control
samples). Reactions were resolved by SDS-PAGE and 32P incorporation
on MBP was estimated by densitometry. Molecules were classified as
active when the residual kinase activity was less than 50% in
comparison to control samples.
doi:10.1371/journal.pone.0052011.g002
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residual kinase activity with respect to control samples containing
no inhibitors: molecules capable of an effect equal or higher than
the threshold were labeled as ‘‘active’’, ‘‘not active’’ otherwise.
The structure-based derived subset was populated by a significant
percentage (20%) of ‘‘active’’ molecules as compared to the ligand-
based approach that showed only 3% of success rate (Fig. 2).
Interestingly, besides the ‘‘active’’ molecules, a high percentage of
the total tested compounds showed at least a partial ability to
decrease ERK8 activity (Table S1). This finding, therefore,
indicates that the modeled 3D kinase domain of the refined
ERK8 has a reliable structure and that, in this specific case, the
structure-based approach is to be preferred over the ligand-based
one to identify molecular scaffolds potentially interesting for
further optimization.
In vitro characterization of selected scaffolds
ITT45, ITT53 and ITT57 (Fig. 4A–B and Table S1), the most
potent identified inhibitors of ERK8 catalytic activity, were
selected among ‘‘active’’ molecules also considering their signifi-
cant chemical diversity. Indeed, the Tanimoto similarity indexes
calculated by using ECFP_6, MDLPublicKeys and FCFP_6 sets of
fingerprints were below 0.1, 0.5 and 0.2 each other, respectively.
Moreover, to the best of our knowledge, this is the first time that
these molecular scaffolds are proposed as ERK inhibitors. The
three compounds were submitted to an in-depth in vitro
characterization aimed at fully validating the refined ERK8
structure and, consequently, the overall computational protocol.
For this purpose, we confirmed the inhibitory effect of the selected
compounds, as found during the preliminary screening, showing a
calculated percentage of residual kinase activity of 3667%,
3568% and 3265% for ITT53, ITT45 and ITT57, respectively
(Fig. 4C and Fig. 4D).
Although widely used as a source of protein kinases for studying
their activity and response to inhibitors [28], it is well established
that E. coli-based bacterial expression systems do not necessarily
ensure a correct post-translational processing of heterologously
expressed proteins, often required for fully and correctly controlled
activity. In this regard, the baculovirus-based insect expression
system has been used to produce recombinant proteins, because
insect cells can perform correct post-translational modification of
heterologous proteins [43]. Based on this information, we next
Figure 3. Pharmacophore models. (A), Left panel, Structure-based pharmacophore generated from the Mg++ loaded ERK8/ADP complex
(coordinates were taken from the refined ERK8 structure) by using the Ligandscout software. Right panel, Structure-based pharmacophore generated
by the GRID-based pharmacophore modeling approach, starting from the ligand-bound refined structure of ERK8. Features code: HYD=hydrophobic;
HBA=H-bond acceptor; HBD=H-bond donor; AROM=aromatic ring; grey spheres are excluded volumes. (B), The two ligand-based pharmacophores
generated with the training set of 18 different inhibitors active towards ERK8 (from Bain J, et al., 2007). Features code same as above.
doi:10.1371/journal.pone.0052011.g003
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decided to test our compounds on GST-ERK8 produced from
baculovirus-infected insect cells. GST-ERK8 purified through this
system (hereafter named GST-ERK8Bac) was then used in classical
kinase assays to test the three scaffolds. ITT53 and ITT57 efficacy
was almost equivalent to that observed with bacterially expressed
protein (i.e., 3266% and 2666% of residual kinase activity,
respectively), whereas, surprisingly, no effect was obtained by using
ITT45 (Fig. 4E and Fig. 4F). This observation showed the
importance of confirming the results obtained from bacterially-
produced ERK8 also by using an eukaryotic expression system
and also suggested a potentially specific role for post-translational
modifications in the regulation of ERK8 activity. Based on this
evidence, we decided to perform additional characterization only
on ITT53 and ITT57, which gave best chances to affect fully
active ERK8. Dose/response curves were then carried out on
GST-ERK8Bac and estimated half-maximal inhibitory concentra-
tion (IC50) values for ITT53 and ITT57 were 27 mM (95%
confidence interval 8–84 mM) and 17 mM (95% confidence
interval 6–48 mM), respectively (Fig. 5A). Next, we tested ITT53
and ITT57 in a competition assay with different concentrations of
ATP. As reported in Figure 5B, increasing ATP concentrations
induced a decrease in the inhibitory action of ITT53 and ITT57.
This profile was compatible with a competitive mechanism with
the natural substrate, and indirectly supported the reliability of our
ERK8 kinase domain model that has been used to select these
ATP binding pocket small molecule inhibitors. As an additional
control, the ATP competition assay profile of ITT53 and ITT57
displayed the same characteristics of the positive control Ro-
318220 (Fig. 5B), already described as an ATP competitive kinase
inhibitor [42]. Altogether, these results indicate that the two
molecules are able to inhibit the kinase activity of the full-length
protein expressed both in E. coli and in a eukaryotic system. The
IC50 values represent a valuable starting point for molecules
obtained from a first ‘‘in silico-in vitro’’ screening process. They also
show a behavior that is compatible with a competition mechanism
with the natural substrate ATP.
Binding Mode Analysis
The mechanism of action assessed by means of the previously
described ATP competition assay was a solid indication that the
selected molecules occupy the ATP cavity, as predicted. Moreover,
being the demonstration of the binding mode particularly
important to solidly validate our computational assumptions, we
decided to deal with this issue also by an alternative approach. We
took advantage of the so-called ‘‘chemical genetic analysis’’, first
performed by Shokat and co-workers [44] through the generation
of engineered kinases sensitive to inhibitors and ATP analogues,
which are not equally effective on wild type proteins. Indeed, a
single residue in the ATP binding pocket of protein kinases,
termed the ‘‘gatekeeper’’, has been shown to control sensitivity to a
wide range of small molecule inhibitors [45–47]. Therefore, we
hypothesized that perturbing the ATP cavity of ERK8 by
mutating its ‘‘gatekeeper’’ residue would affect the affinity of the
ITT53 and ITT57 molecules only in case they bind to this specific
region. This would confirm an ATP competitive mechanism of
action for these hit compounds, as predicted by calculations and
previously suggested with in vitro assays (Fig. 4B and Fig. 5B). Our
analysis showed that the gatekeeper position of ERK8 (residue 92)
is occupied by a phenylalanine (Phe, F) (Fig. 6A), differently from
the templates used for the modeling (a glutamine for both FUS3
and ERK2) but similarly, for example, to members of the CDK
family. Indeed, superimposition of our model to a high resolution
CDK2 X-ray structure confirmed the local structural similarity in
the gatekeeper surroundings between these two proteins (Fig. 6B),
further supporting the reliability of our computational model.
Based on this analysis and on previous studies of the gatekeeper
position of CDK2 (CDK2_F80G) [48,49], we decided to generate
an ERK8 gatekeeper mutant substituting the Phe92 with a smaller
glycine (Gly, G) residue. Unexpectedly, ERK8_F92G showed an
almost complete loss in catalytic activity (Fig. 6D). Indeed, thanks
to the broad use of the chemical genetic analysis, evidences about
the ability of many kinases to tolerate dramatic mutations at the
gatekeeper position have accumulated but, more recently, it has
also become clear that many kinases do not tolerate such
perturbations [50,51]. These kinases (roughly 30% of tested
kinases), that undergo loss of catalytic activity and/or cellular
function upon introduction of space-creating gatekeeper muta-
tions, have been classified as ‘‘intolerant’’, unlike the ‘‘tolerant’’
ones that, in these conditions, are able to maintain their catalytic
functions [51]. Although the selected structural templates FUS3
and ERK2, and the ‘‘gatekeeper-related’’ CDK2 protein all
belong to the group of ‘‘tolerant’’ kinases, the ERK8_F92G loss of
activity suggests that this protein could, therefore, represent a new
‘‘intolerant’’ kinase. In order to better investigate this aspect, we
generated other three gatekeeper mutants substituting the
phenylalanine with chemically different residues, namely another
small amino acid, alanine (Ala, A), and two bulkier amino acids
such as isoleucine (Ile, I) and tyrosine (Tyr, Y). All the generated
single-point ERK8 mutants in the gatekeeper position, F92G,
F92A, F92I, and F92Y, were expressed as N-terminal GST-tagged
proteins in E. coli with the same procedure applied to the wild type
protein. Purified fusion proteins were also controlled for correct
identity via western blot analysis using a specific anti-ERK8
antibody, also demonstrating the expected molecular weight as
compared to the wild type and kinase dead (ERK8_KD) proteins
(Fig. 6C). Interestingly, all but the ERK8_F92I mutant showed a
barely detectable basal activity in the kinase assay when it was
measured in comparison to the wild type protein (Fig. 6D). These
results support the classification of ERK8 as a new ‘‘intolerant’’
kinase to the mutation of the gatekeeper residue to glycine or
alanine.
Being our goal the confirmation of the selected scaffolds binding
mode and also the evaluation of the predictive value of ERK8
model, we next decided to focus our analysis only on the partially
active ERK8_F92I mutant. Therefore, we generated the
ERK8_F92I model with the same computational protocol applied
to ERK8 wild type (WT). Then, we chose to analyze the
interaction pattern of both modeled structures with one of our
Figure 4. Effect of selected molecular scaffolds on bacterial and eukaryotic GST-ERK8. (A), Molecular structure of selected compounds.
(B), Binding mode of each compound as obtained after the molecular docking step. The ITT molecules are showed as sticks and colored by atom type.
ERK8 protein structure is represented by secondary structure cyan elements. (C), Samples of GST-ERK8 from E. coli with the indicated concentration of
inhibitors were subjected to kinase assay. Reactions were resolved by SDS-PAGE and 32P incorporation on MBP was estimated by densitometry
(upper panel). Coomassie staining verified that equal amounts of substrate were loaded (lower panel). (D), The average results of three independent
experiments done in duplicate 6 SD are plotted. (E), Samples of GST-ERK8Bac with the indicated concentration of inhibitors were subjected to kinase
assay. Reactions were resolved by SDS-PAGE and 32P incorporation on MBP was estimated by densitometry (upper panel). Coomassie staining verified
that equal amounts of substrate were loaded (lower panel). (F), The average results of three independent experiments done in duplicate 6 SD are
plotted.
doi:10.1371/journal.pone.0052011.g004
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selected compounds. To this purpose, both ERK8_WT and
ERK8_F92I, in complex with ITT57, were relaxed during 2 ns of
unrestrained MD. The ITT57 delta energy of binding was
calculated by means of the MMPBSA approach [52], showing that
the substitution of the Phe92 aromatic ring with the aliphatic chain
of isoleucine is associated to a higher delta energy of interaction.
From a structural point of view, analysis of representative MD
structures (Fig. 7A) revealed that the overall binding mode of
ITT57 within the catalytic site is the same in both protein
structures, although the methoxyphenyl moiety seems to be less
buried into the lipophilic pocket of the ERK8_F92I mutant than
into the wild type one. These differences, together with the
possible enthalpy gain coming from a pi-pi stacking interaction
between the Phe92 gatekeeper residue of ERK8_WT and ITT57,
would suggest a less profitable interaction of ITT57 with the
ERK8_F92I mutant than with the WT. Therefore, based on this
in silico analysis, we could predict a decreased efficacy of ITT57 on
the ERK8_F92I mutant. We next performed the conclusive
Figure 5. In vitro characterization. (A), Dose/response curves for ITT53 and ITT57 on GST-ERK8Bac. Results are reported as residual MBP
phosphorylation levels compared with the control (DMSO). The average results of two independent experiments done in triplicate 6 SD are plotted
with the curve-fitting PRISM software (GraphPad). The concentration of drug that inhibited activity by 50% (IC50) is shown. (B), ITT53, ITT57 and Ro-
318220 ATP competition assay on GST-ERK8Bac. Inhibition values are reported as percentage of residual MBP phosphorylation levels (i.e., residual
kinase activity) compared with the control (DMSO). Results for the two indicated concentrations of ITT53, ITT57 and Ro-318220 (top, middle, bottom
panel, respectively) at four different ATP doses were plotted. The average results of two independent experiments done in triplicate6 SD are plotted.
doi:10.1371/journal.pone.0052011.g005
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experimental test to assess the binding mode of ITT53 and ITT57
by comparing ERK8_F92I and ERK8_WT inhibition profiles,
this approach also giving us the possibility to challenge the
theoretical prediction about ERK8_F92I increased resistance to
ITT57. As a control, we also tested, in the same kinase assay, the
Ro-318220 ATP competitive inhibitor [42]. As expected, we
observed that the inhibitory activity of Ro-318220 was affected by
the presence of the F92I mutation in ERK8, in particular being
Figure 6. Gatekeeper mutants. (A), Multiple sequence alignment of gatekeeper region among different members of the MAPK and CDK families
of kinases. The position corresponding to the gatekeeper residue is highlighted. (B), Superimposition of the refined ERK8 structure (cyan) and CDK2
(magenta) X-ray structure. (C), Western Blot control of GST-fusion proteins from E. coli. Each lane was loaded with 100 ng of purified protein. ERK8_KD
sample (lane 6) is a point mutant on the conserved lysine (Lys, K) in position 42 to arginine (Arg, R). (D), Representative kinase assay blot of
gatekeeper mutants (200 ng/sample of purified protein) (upper panel). Reactions were resolved by SDS-PAGE and 32P incorporation on MBP was
estimated by densitometry. Coomassie staining verified that equal amounts of substrate were loaded (lower panel). Quantification of kinase activity
in comparison to WT, as scored by MBP phosphorylation, from three independent experiments is reported in the lower panel.
doi:10.1371/journal.pone.0052011.g006
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more active on the wild type than on the mutated ERK8 protein
(Fig. 7B and Fig. S5). Similarly, ITT53 and ITT57 molecules were
also significantly more active on ERK8_WT than on ERK8_F92I,
proving that this kind of perturbation at the gatekeeper position
gives rise to an ERK8 protein more resistant to inhibition
triggered by small molecules that occupy the catalytic pocket.
More importantly, this result both emphasizes the predictive
ability of our model and confirms the competition assays data,
ultimately showing that the selected scaffolds bind ERK8 in the
ATP cavity.
Discussion
Over the past decade, protein kinases raised as the pharma-
ceutical industry’s most popular drug targets, especially in the field
of cancer. In particular, interest in MAPKs has recently exploded
[53,54]. Also, chemical inhibitors, both the clinically relevant ones
and many other molecules that do not reach the latest stages of
approval procedures, have become invaluable reagents for
studying the physiological functions of their target protein.
However, the ATP binding sites with which most inhibitors
interact, are highly conserved throughout the large kinase family,
raising an acute specificity problem. Indeed, although this may
Figure 7. A resistant ERK8_F92I mutant confirms the predicted ATP pocket-binding mode. (A), Representative structures from MD
simulation of the complex between ITT57 and both ERK8_WT (left panel) and ERK8_F92I mutant (right panel). The residue at position 92 is labeled
and showed as sticks. The ITT57 ligand is showed as sticks. Protein residues and ligand atoms are colored by atom type. (B), GST tagged ERK8_WT and
ERK8_F92I proteins (200 ng/sample) were used in kinase assays in presence of the indicated concentrations of ITT53, ITT57 and Ro-318220 molecules.
Using the paper-spotted kinase assay technique, we quantified and normalized the activities of the WT and of the mutant protein. MBP
phosphorylation levels were evaluated by b-counting protocol of triplicates and results expressed as percentage of residual kinase activity compared
with control samples. Significance (p-value) was obtained by one-way ANOVA test. Asterisks were attributed for the following significance values:
p,0.05 (*), p,0.01 (**), p,0.001 (***).
doi:10.1371/journal.pone.0052011.g007
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sometimes be an advantage when it comes to clinical effect, most
commercially available chemical inhibitors of protein kinases are
poorly specific [28].
Knowledge about ERK8 targets and downstream effectors and,
ultimately, about its biological functions is still limited. Among
currently available data suggesting a role for this kinase in normal
and aberrant cell proliferation [10], the recent observation about
ERK8 being a potent regulator of telomerase activity [12] clearly
shows the possibility of a beneficial use for pharmacological ERK8
inhibition. More specifically, it is shown that ERK8 pharmaco-
logical inhibition results in a significant decrease in telomerase
activity, which tumor cells often activate to bypass replicative
senescence and gain unlimited proliferation ability. In particular,
Ro-318220 has been used to confirm the ERK8-dependent
telomerase activity in transformed cell lines [12]. Altogether, these
data strongly support the clinical potential of ERK8 inhibition.
The gap of knowledge to fill up about ERK8 signaling and the
absence of a crystal structure led us to apply an in silico protocol to
generate a 3D model of the ERK8 kinase domain and to screen,
first in silico and then in vitro, molecular scaffolds to validate the
ERK8 structure itself. As described above, whereas the structure-
based derived subset showed a significant percentage (20%) of
active molecules, the ligand-based approach only showed a 3%
success rate. Although disappointing, such a low success rate
indicated that the ERK8 inhibition observed with the other set of
molecules was not a random effect based on an intrinsic high
propensity of ERK8 for chemical inhibition.
Next, the structure-based model provided a valuable guidance
in the screening of ATP competitive inhibitors, allowing us to
identify a high percentage of in vitro active compounds (though
with different effectiveness), despite the limited number of
screened molecules. This result, together with the confirmation
of their ability to target the ATP binding pocket, demonstrates that
the generated ERK8 model is a reliable tool for the screening of
novel inhibitors. These scaffolds, for the first time specifically
selected towards the ERK8 ATP pocket, in turn can be worthy of
further chemical optimization to increase and finely tune their
potency.
Ultimately, this work also led us to the identification of an
ERK8 drug-resistant mutant, namely ERK8_F92I, that not only
proved the expected binding mode of our molecules, but could
pave the way to the use of synthetic ATP analogues for the
identification of ERK8 substrates [55]. Thanks to the study of
gatekeeper mutations, we also demonstrated that space-creating
mutations (i.e., glycine or alanine replacing the natural bulky
phenylalanine) almost completely abolish kinase activity. Hence,
we propose ERK8 as another member of the so-called ‘‘intoler-
ant’’ group of kinases, as defined by Shokat and co-workers [51].
Altogether, our results suggest that the generated model will be an
important resource for the identification of specific inhibitors for
the ERK8 MAP kinase.
Conclusions
A well-developed body of knowledge identifies different MAPKs
as critical regulators of cell proliferation and human cancer.
Several recently developed pharmacological inhibitors targeting
MAPKs have been effective in animal models and have therefore
advanced to clinical trials for the treatment of inflammatory
diseases and cancer. Still, although the specific ERK8 member of
this family has been proposed as a novel potential therapeutic
target for cancer, the lack of its experimental structure currently
limits the possibilities to efficiently look for pharmacological
compounds specifically targeting this kinase. As a consequence, the
development of new therapeutic strategies based on molecular and
pharmacological intervention on ERK8 functions is currently
impaired. We believe that our results show that the 3D ERK8
model we generated is a reliable tool to be exploited in a drug-
design perspective. Consequently, future work about this atypical
MAPK will largely benefit of the identification of a sufficiently
specific inhibitor to dissect its signaling functions and to further
validate its potential as a novel therapeutic target in cancer
treatment.
Supporting Information
Figure S1 T-Coffee multiple sequence alignment. Multi-
ple sequence alignment between FUS3, ERK2 and ERK8
obtained with T-Coffee software (standard protocol). Consensus
code: ‘‘yellow’’ indicates positions which have a single, fully
conserved residue; ‘‘green’’ indicates conservation between groups
of strongly similar properties; ‘‘blue’’ indicates conservation
between groups of weakly similar properties. The TEY activation
motif is in red.
(DOC)
Figure S2 ERK8 model and FUS3. (A), Superimposition of
the ERK8 model (grey) with the FUS3 template (blue). (B),
Superimposition of the refined ERK8 structure (cyan) with the
FUS3 template (blue). (C), ADP binding mode within the catalytic
pocket. In green sticks is showed the crystallographic binding
mode of ADP within the FUS3 template. In grey sticks is showed
the ADP binding mode in the ERK8 structure refined by
molecular dynamics. In magenta sticks is showed ADP binding
mode as obtained by self-docking ADP toward the refined ERK8
structure by the GOLD docking program. Heteroatoms are
colored by atom types.
(DOC)
Figure S3 Stability of MD. Root mean square deviation
(rmsd) of each frame with respect to the first frame of unrestrained
MD, over time.
(DOC)
Figure S4 Ligand-based approach: the training set. List
of compounds used to generate the two ligand-based pharmaco-
phores (from Bain J, et al., 2007).
(DOC)
Figure S5 Kinase Assay of GST-tagged ERK8 proteins
on autophosphorylation. (A), Representative kinase assay blot
of WT and different ERK8 mutants (200 ng/sample of purified
protein) (upper panel). Reactions were resolved by SDS-PAGE
and 32P incorporation on GST-ERK8 proteins themselves was
estimated by densitometry. Quantification of kinase activity in
comparison to WT, as scored by autophosphorylation, from three
independent experiments is reported in the lower panel. (B), GST
tagged ERK8_WT and ERK8_F92I proteins (200 ng/sample)
were used in kinase assays in presence of the indicated
concentrations of ITT53, ITT57 and Ro-318220 molecules.
Using the paper-spotted kinase assay technique, we quantified
and normalized the activities of the WT and of the mutant protein.
Autophosphorylation levels were evaluated by b-counting protocol
of triplicates and results expressed as percentage of residual kinase
activity compared with control samples.
(DOC)
Table S1 Experimental Screening results for the struc-
ture-based selected molecules. Ranking of all the molecules
obtained with the structure-based approach: the percentage (in
brackets) of residual kinase activity is reported for all the
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compounds. (a) residual kinase activity with respect to control
samples containing no inhibitors (b) ratio between the number of
active molecules and the number of tested molecules (c) success rate
obtained for threshold activity up to 55% (d) success rate obtained
for threshold activity up to 65%.
(DOC)
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